2026-01-17 - Analysis Report
**Company Overview**
Northrop Grumman Corp is a leading global aerospace and defense technology company.

**Return Rate Comparison**
* Review Stock (NOC): Cumulative Return = **60.09%**
* Comparison Stock (VOO): Cumulative Return = **93.36%**
* Divergence (max: 47.60, min: -59.70, current: -36.10, relative divergence: 22.00%)

The review stock has a lower cumulative return compared to the comparison stock, indicating a potential divergence in performance. The negative divergence suggests that the review stock is underperforming compared to the market.

**Alpha, Beta Analysis**

| Year   | CAGR  | MDD  | Alpha | Beta | Cap(B) |
|--------|-------|------|-------|------|--------|
| 2016-2018| -6.0% | 23.7% | -10.0% | 0.7 | 35.1B |
| 2017-2019| 15.0% | 23.7% | -2.0% | 0.7 | 49.2B |
| 2018-2020| -25.0% | 23.7% | -46.0% | 0.8 | 43.6B |
| 2019-2021| 40.0% | 12.9% | -3.0% | 0.7 | 55.4B |
| 2020-2022| 18.0% | 16.9% | 19.0% | 0.6 | 78.1B |
| 2021-2023| 23.0% | 16.9% | 22.0% | 0.3 | 67.0B |
| 2022-2024| -14.0% | 16.9% | -33.0% | 0.3 | 67.2B |
| 2023-2025| -1.0% | 17.7% | -63.0% | 0.1 | 81.6B |

The review stock has varying CAGR and MDD values across different periods, indicating fluctuating performance. The Alpha values are generally negative, except for the 2020-2022 period, indicating underperformance compared to the market. The Beta values are relatively high, indicating high volatility.

**Recent Stock Price Fluctuations**

* Close: **$666.90**
* 5-day SMA: **$645.89**
* 20-day SMA: **$599.93**
* 60-day SMA: **$579.36**

The review stock's price is currently above its short-term moving averages but below its long-term moving averages, indicating a potentially overbought condition.

**RSI, PPO Index and Delta Prevous Divergence**

* Market Risk Indicator (MRI): **0.80**
* RSI: **74.74**
* PPO: **1.29**
* Hybrid Signal: **Buy (Cash 0%)**

The review stock's RSI and PPO values are high, indicating overbought conditions. The MRI value indicates a medium-risk investment.

**Expected Return**
* Expected Return (%): **-46.30%**

The review stock has a negative expected return compared to the market, indicating a potential long-term underperformance.

**Recent News & Significant Events**

* Northrop Grumman (NOC) Is Up 10.8% After Winning Marine Corps Valkyrie MUX Autonomy Contract
* Focused Investors LLC Purchases 8,300 Shares of Northrop Grumman Corporation $NOC
* Whatâ€™s The Risk For Northrop Grumman Stock As Trump Curbs Dividends And Executive Pay?
* Northrop Grumman Stock: $1.5 Trillion Defense Budget Boosts F/A-XX Win (NYSE:NOC)
* UBS Keeps Their Buy Rating on Northrop Grumman (NOC)
* How to Buy Northrop Grumman Stock (NOC)

The review stock has recently received positive news regarding a major contract win and a buy rating from a prominent analyst.

**Analyst Opinions**

* Key: Buy
* Mean (1=StrongBuy~5=Sell): **2.09 (~Buy)**
* Opinions: **21**
* Target Price (avg/high/low): **672.87 / 777.00 / 533.00**

The analyst consensus is generally positive, with a mean opinion score of buy and a target price range indicating potential long-term upside.

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|------|-----|----------|
| 2025-10-21| 7.69 | 10.42B$ |
| 2025-07-22| 8.17 | 10.35B$ |
| 2025-04-22| 3.33 | 9.47B$ |
| 2024-10-24| 7.02 | 10.00B$ |
| 2025-10-21| 7.02 | 10.00B$ |

The review stock has recently reported strong earnings, with increasing EPS and revenue values.

**Financial Information - Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $10.42B | 21.37% |
| 2025-06-30 | $10.35B | 21.35% |
| 2025-03-31 | $9.47B | 16.69% |
| 2024-12-31 | $10.69B | 18.08% |
| 2024-09-30 | $10.00B | 21.07% |

The review stock has generally increasing revenue and profit margin values, indicating strong financial performance.

**Financial Information - Capital and Profitability**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $15.99B | 6.88% |
| 2025-06-30 | $15.47B | 7.59% |
| 2025-03-31 | $14.98B | 3.21% |
| 2024-12-31 | $15.29B | 8.27% |
| 2024-09-30 | $14.75B | 6.96% |

The review stock has increasing equity and ROE values, indicating strong capital and profitability.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.